Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan Cilexetil Dose-ranging Study in Hypertensive Children (1-6 Years)
NCT00244621Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Primary completion
- Aug 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of candesartan cilexetil in hypertension (HTN) (3 arms), sponsored by AstraZeneca. Primary endpoint: Systolic Blood Pressure at 4 weeks. Started Nov 2004; status: completed.
02
Drugs
candesartan cilexetil
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00244621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244621.